<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns="http://purl.org/rss/1.0/"><channel rdf:about="http://www.phytomedicinejournal.com/?rss=yes"><title>Phytomedicine</title><description>Phytomedicine RSS feed: Current Issue.    
 Phytomedicine  is published to attract and disseminate innovative and expert findings 
in the fields of phytopharmacology, phytotherapy 
and phytotoxicology, as a reference 
source for researchers in these fields, and with the aim to set international 
standards in their 
methodology. The journal publishes research results on phytotherapy 
(clinical trials), phytopharmacology, pharmacognosy, standardization 
and phytotoxicology, 
obtained with plant extracts as well as isolated compounds from these extracts 
and phytopharmaceuticals. Phytomedicine 
is targeted towards papers of a practical 
nature. The papers published in this journal are also useful to drug regulatory 
authorities 
in deciding whether to approve certain phytomedicines or not. Phytomedicine 
consists of the following sections: Case reports, Pharmacological 
and molecularbiological 
studies, Screening studies (only when focused on plant extracts or isolated compounds 
with extraordinary activities, 
Chemical structure - activity studies, Chemical 
analysis and standardization of plant drugs and phytopharmaceuticals, Reviews 
(by invitation).

 For more information, go to    http://www.elsevier.de/phymed 
   </description><link>http://www.phytomedicinejournal.com/?rss=yes</link><dc:publisher>Elsevier Inc.</dc:publisher><dc:language>en</dc:language><dc:rights> © 2012 Published by Elsevier Inc. All rights reserved. </dc:rights><prism:publicationName>Phytomedicine</prism:publicationName><prism:issn>0944-7113</prism:issn><prism:volume>19</prism:volume><prism:number>7</prism:number><prism:publicationDate>15 May 2012</prism:publicationDate><prism:copyright> © 2012 Published by Elsevier Inc. All rights reserved. </prism:copyright><prism:rightsAgent>healthpermissions@elsevier.com</prism:rightsAgent><items><rdf:Seq><rdf:li rdf:resource="http://www.phytomedicinejournal.com/article/PIIS0944711312001432/abstract?rss=yes"/><rdf:li rdf:resource="http://www.phytomedicinejournal.com/article/PIIS0944711312000360/abstract?rss=yes"/><rdf:li rdf:resource="http://www.phytomedicinejournal.com/article/PIIS0944711312000402/abstract?rss=yes"/><rdf:li rdf:resource="http://www.phytomedicinejournal.com/article/PIIS0944711312000487/abstract?rss=yes"/><rdf:li rdf:resource="http://www.phytomedicinejournal.com/article/PIIS0944711312000505/abstract?rss=yes"/><rdf:li rdf:resource="http://www.phytomedicinejournal.com/article/PIIS0944711312000499/abstract?rss=yes"/><rdf:li rdf:resource="http://www.phytomedicinejournal.com/article/PIIS0944711312000359/abstract?rss=yes"/><rdf:li rdf:resource="http://www.phytomedicinejournal.com/article/PIIS0944711312000396/abstract?rss=yes"/><rdf:li rdf:resource="http://www.phytomedicinejournal.com/article/PIIS0944711312000426/abstract?rss=yes"/><rdf:li rdf:resource="http://www.phytomedicinejournal.com/article/PIIS0944711312000438/abstract?rss=yes"/><rdf:li rdf:resource="http://www.phytomedicinejournal.com/article/PIIS0944711312000451/abstract?rss=yes"/><rdf:li rdf:resource="http://www.phytomedicinejournal.com/article/PIIS0944711312000517/abstract?rss=yes"/><rdf:li rdf:resource="http://www.phytomedicinejournal.com/article/PIIS0944711312000372/abstract?rss=yes"/><rdf:li rdf:resource="http://www.phytomedicinejournal.com/article/PIIS0944711312000918/abstract?rss=yes"/></rdf:Seq></items></channel><item rdf:about="http://www.phytomedicinejournal.com/article/PIIS0944711312001432/abstract?rss=yes"><title>Editorial Board</title><link>http://www.phytomedicinejournal.com/article/PIIS0944711312001432/abstract?rss=yes</link><description></description><dc:title>Editorial Board</dc:title><dc:creator></dc:creator><dc:identifier>10.1016/S0944-7113(12)00143-2</dc:identifier><dc:source>Phytomedicine 19, 7 (2012)</dc:source><dc:date>2012-05-15</dc:date><prism:publicationName>Phytomedicine</prism:publicationName><prism:publicationDate>2012-05-15</prism:publicationDate><prism:volume>19</prism:volume><prism:number>7</prism:number><prism:issueIdentifier>S0944-7113(12)X0005-9</prism:issueIdentifier><prism:section></prism:section><prism:startingPage>CO2</prism:startingPage><prism:endingPage>CO2</prism:endingPage></item><item rdf:about="http://www.phytomedicinejournal.com/article/PIIS0944711312000360/abstract?rss=yes"><title>Non-insulin dependent anti-diabetic activity of (2S, 3R, 4S) 4-hydroxyisoleucine of fenugreek (Trigonella foenum graecum) in streptozotocin-induced type I diabetic rats</title><link>http://www.phytomedicinejournal.com/article/PIIS0944711312000360/abstract?rss=yes</link><description>Abstract: The seeds of fenugreek, Trigonella foenum graecum, commonly used as a spice in Middle Eastern countries and widely used in south Asia and Europe, are known to have anti-diabetic properties. They contain an unusual amino acid (2S, 3R, 4S) 4-hydroxyisoleucine (4HO-Ile), so far found only in fenugreek, which has anti-diabetic properties of enhancing insulin secretion under hyperglycaemic conditions, and increasing insulin sensitivity. Here we describe for the first time the anti-diabetic activity of 4HO-Ile in a model of type I diabetes, streptozotocin-treated rats, where levels of insulin are much reduced, by 65%, compared to normal animals. Treatment of diabetic rats with daily doses of 4HO-Ile at 50mg/kg/day for four weeks could reduce plasma glucose in the diabetic group. Moreover the high levels of lipids (cholesterol, HDL, LDL and triglycerides) and uric acid in the diabetic rats, could be restored to levels found in non-diabetic controls by the treatment with 4HO-Ile. These results demonstrate that 4HO-Ile has significant anti-diabetic activities that are independent of insulin and suggest the potential of 4HO-Ile as an adjunct to diabetes treatment and for type 1 as well as type 2 diabetes.</description><dc:title>Non-insulin dependent anti-diabetic activity of (2S, 3R, 4S) 4-hydroxyisoleucine of fenugreek (Trigonella foenum graecum) in streptozotocin-induced type I diabetic rats</dc:title><dc:creator>Mohammed R. Haeri, Hamidreza Khalatbari Limaki, Christopher J. Branford White, Kenneth N. White</dc:creator><dc:identifier>10.1016/j.phymed.2012.01.004</dc:identifier><dc:source>Phytomedicine 19, 7 (2012)</dc:source><dc:date>2012-03-07</dc:date><prism:publicationName>Phytomedicine</prism:publicationName><prism:publicationDate>2012-03-07</prism:publicationDate><prism:volume>19</prism:volume><prism:number>7</prism:number><prism:issueIdentifier>S0944-7113(12)X0005-9</prism:issueIdentifier><prism:section>Diabetes and Endocrinology</prism:section><prism:startingPage>571</prism:startingPage><prism:endingPage>574</prism:endingPage></item><item rdf:about="http://www.phytomedicinejournal.com/article/PIIS0944711312000402/abstract?rss=yes"><title>Cannabis exposure associated with weight reduction and β-cell protection in an obese rat model</title><link>http://www.phytomedicinejournal.com/article/PIIS0944711312000402/abstract?rss=yes</link><description>Abstract: The aim of this study was to investigate the effect of an organic cannabis extract on β-cell secretory function in an in vivo diet-induced obese rat model and determine the associated molecular changes within pancreatic tissue. Diet-induced obese Wistar rats and rats fed on standard pellets were subcutaneously injected with an organic cannabis extract or the vehicle over a 28-day period. The effect of diet and treatment was evaluated using the intraperitoneal glucose tolerance tests (IPGTTs) and qPCR analysis on rat pancreata harvested upon termination of the experiment.The cafeteria diet induced an average weight difference of 32g and an overall increase in body weight in the experimental groups occurred at a significantly slower rate than the control groups, irrespective of diet. Area under the curve for glucose (AUCg) in the obese group was significantly lower compared to the lean group (p&lt;0.001), with cannabis treatment significantly reducing the AUCg in the lean group (p&lt;0.05), and remained unchanged in the obese group, relative to the obese control group. qPCR analysis showed that the cafeteria diet induced down-regulation of the following genes in the obese control group, relative to lean controls: UCP2, c-MYC and FLIP. Cannabis treatment in the obese group resulted in up-regulation of CB1, GLUT2, UCP2 and PKB, relative to the obese control group, while c-MYC levels were down-regulated, relative to the lean control group. Treatment did not significantly change gene expression in the lean group. These results suggest that the cannabis extract protects pancreatic islets against the negative effects of obesity.</description><dc:title>Cannabis exposure associated with weight reduction and β-cell protection in an obese rat model</dc:title><dc:creator>R-A. Levendal, D. Schumann, M. Donath, C.L. Frost</dc:creator><dc:identifier>10.1016/j.phymed.2012.02.001</dc:identifier><dc:source>Phytomedicine 19, 7 (2012)</dc:source><dc:date>2012-03-16</dc:date><prism:publicationName>Phytomedicine</prism:publicationName><prism:publicationDate>2012-03-16</prism:publicationDate><prism:volume>19</prism:volume><prism:number>7</prism:number><prism:issueIdentifier>S0944-7113(12)X0005-9</prism:issueIdentifier><prism:section>Diabetes and Endocrinology</prism:section><prism:startingPage>575</prism:startingPage><prism:endingPage>582</prism:endingPage></item><item rdf:about="http://www.phytomedicinejournal.com/article/PIIS0944711312000487/abstract?rss=yes"><title>Silymarin regulates the cytochrome P450 3A2 and glutathione peroxides in the liver of streptozotocin-induced diabetic rats</title><link>http://www.phytomedicinejournal.com/article/PIIS0944711312000487/abstract?rss=yes</link><description>Abstract: This study aimed to investigate the protective and regulatory effects of silymarin (SMN) and melatonin (MEL) on streptozotocin (STZ)-induced diabetic changes in cytochrome P450 3A2 (CYP 3A2) and glutathione peroxidase (GPX) expression and antioxidant status in the liver. Male Wistar rats were divided into five groups, including: control (C), untreated diabetic animals (D), SMN-treated diabetics (S, 50mg/kg, orally), MEL-treated diabetics (M, 10mg/kg, i.p.), and SMN plus MEL-treated diabetics (S+M). Diabetes was induced by a single intraperitoneal injection of STZ (50mg/kg). The blood glucose level, daily urinary volume and body weight changes were measured. After the 28 days treatment period, antioxidant status was analyzed by means of the determination of malondialdehyde (MDA) content, nitric oxide (NO) and total thiol molecules (TTM) levels in the liver. The glycogen depletion in the liver was examined by histochemical staining. The CYP 3A2 and GPX expression at mRNA level was determined using RT-PCT technique. SMN and MEL both individually or in combination prevented from diabetes-induced weight loss and lowered daily urinary volume significantly (p&lt;0.05). None of the test compounds could lower the blood glucose level significantly (p&gt;0.05). Both SMN and MEL could convert the diabetes induced elevated levels of MDA and NO and the diabetes-reduced TTM content to the control level. Moreover, the diabetes-up regulated CYP 3A2 and down regulated GPX, returned to normal values after SMN treatment. Histochemical and histopathological examinations revealed that the diabetes-induced glycogen-depletion and single cell necrosis markedly improved with the SMN and SMN plus MEL treatment. Our data suggest that the STZ-induced diabetes in addition of disturbing the antioxidant status, alters the expression levels of CYP 3A2 and GPX. Moreover, the SMN and SMN plus MEL treatment was able to normalize both the antioxidant status and the expression of CYP 3A2 and GPX in the liver of diabetic rats.</description><dc:title>Silymarin regulates the cytochrome P450 3A2 and glutathione peroxides in the liver of streptozotocin-induced diabetic rats</dc:title><dc:creator>H. Malekinejad, A. Rezabakhsh, F. Rahmani, R. Hobbenaghi</dc:creator><dc:identifier>10.1016/j.phymed.2012.02.009</dc:identifier><dc:source>Phytomedicine 19, 7 (2012)</dc:source><dc:date>2012-03-27</dc:date><prism:publicationName>Phytomedicine</prism:publicationName><prism:publicationDate>2012-03-27</prism:publicationDate><prism:volume>19</prism:volume><prism:number>7</prism:number><prism:issueIdentifier>S0944-7113(12)X0005-9</prism:issueIdentifier><prism:section>Diabetes and Endocrinology</prism:section><prism:startingPage>583</prism:startingPage><prism:endingPage>590</prism:endingPage></item><item rdf:about="http://www.phytomedicinejournal.com/article/PIIS0944711312000505/abstract?rss=yes"><title>Participation of cholinergic pathways in α-hederin-induced contraction of rat isolated stomach strips</title><link>http://www.phytomedicinejournal.com/article/PIIS0944711312000505/abstract?rss=yes</link><description>Abstract: The dry extract of Hedra helix leaves and its main active compounds, predominantly α-hederin and hederacoside C, has been traditionally believed to act spasmolytic. However, it has been recently proved that both, the extract of ivy and triterpenoid saponins, exhibit strong contractile effect on rat isolated stomach smooth muscle strips. It turned out that the most potent contractile agent isolated from the extract of ivy leaves is α-hederin. Thus, it seems reasonable to estimate the mechanism of the contractile effect of this saponin.The presented study was aimed at verifying the participation of cholinergic pathways (muscarinic and nicotine receptors) in α-hederin-induced contraction. The experiments were carried out on rat isolated stomach corpus and fundus strips under isotonic conditions. The preparations were preincubated with either atropine or hexamethonium and then exposed to α-hederin. All results are expressed as the percentage of the response to acetylcholine – a reference contractile agent.The obtained results revealed that the pretreatment of isolated stomach strips (corpus and fundus) with atropine neither prevented nor remarkably reduced the reaction of the preparations to α-hederin. Similarly, if the application of saponin was preceded by the administration of hexamethonium, the strength of the contraction of stomach fundus strips induced by α-hederin was not modified.Concluding, it can be assumed that the cholinergic pathways do not participate in α-hederin-evoked contraction of rat isolated stomach preparations.</description><dc:title>Participation of cholinergic pathways in α-hederin-induced contraction of rat isolated stomach strips</dc:title><dc:creator>M. Mendel, M. Chłopecka, N. Dziekan, W. Karlik, M. Wiechetek</dc:creator><dc:identifier>10.1016/j.phymed.2012.02.011</dc:identifier><dc:source>Phytomedicine 19, 7 (2012)</dc:source><dc:date>2012-04-05</dc:date><prism:publicationName>Phytomedicine</prism:publicationName><prism:publicationDate>2012-04-05</prism:publicationDate><prism:volume>19</prism:volume><prism:number>7</prism:number><prism:issueIdentifier>S0944-7113(12)X0005-9</prism:issueIdentifier><prism:section>Gastroenterology</prism:section><prism:startingPage>591</prism:startingPage><prism:endingPage>595</prism:endingPage></item><item rdf:about="http://www.phytomedicinejournal.com/article/PIIS0944711312000499/abstract?rss=yes"><title>In vitro antimicrobial activity of pannarin alone and in combination with antibiotics against methicillin-resistant Staphylococcus aureus clinical isolates</title><link>http://www.phytomedicinejournal.com/article/PIIS0944711312000499/abstract?rss=yes</link><description>Abstract: The in vitro antimicrobial activities of pannarin, a depsidone isolated from lichens, collected in several Southern regions of Chile (including Antarctica), was evaluated alone and in combination with five therapeutically available antibiotics, using checkerboard microdilution assay against methicillin-resistant clinical isolates strains of Staphylococcus aureus. MIC90, MIC50, as well as MBC90 and MBC50, were evaluated. A moderate synergistic action was observed in combination with gentamicin, whilst antagonism was observed in combination with levofloxacin. All combinations with erythromycin were indifferent, whilst variability was observed for clindamycin and oxacillin combinations. Data from checkerboard assay were analysed and interpreted using the fractional inhibitory concentration index and the response surface approach using the ΔE model. Discrepancies were found between both methods for some combinations. In order to asses cellular lysis after exposure to pannarin, cell membrane permeability assay was performed. The treatment with pannarin produces bactericidal activity without significant calcein release, consistent with lack of lysis or even significant structural damage to the cytoplasmic membrane. Furthermore, pannarin shows low hemolytic activity and moderate cytotoxic effect on peripheral blood mononuclear cells. These findings suggest that the natural compound pannarin might be a good candidate for the individualization of novel templates for the development of new antimicrobial agents or combinations of drugs for chemotherapy.</description><dc:title>In vitro antimicrobial activity of pannarin alone and in combination with antibiotics against methicillin-resistant Staphylococcus aureus clinical isolates</dc:title><dc:creator>Giuseppe Celenza, Bernardetta Segatore, Domenico Setacci, Pierangelo Bellio, Fabrizia Brisdelli, Marisa Piovano, Juan A. Garbarino, Marcello Nicoletti, Mariagrazia Perilli, Gianfranco Amicosante</dc:creator><dc:identifier>10.1016/j.phymed.2012.02.010</dc:identifier><dc:source>Phytomedicine 19, 7 (2012)</dc:source><dc:date>2012-03-29</dc:date><prism:publicationName>Phytomedicine</prism:publicationName><prism:publicationDate>2012-03-29</prism:publicationDate><prism:volume>19</prism:volume><prism:number>7</prism:number><prism:issueIdentifier>S0944-7113(12)X0005-9</prism:issueIdentifier><prism:section>Infections</prism:section><prism:startingPage>596</prism:startingPage><prism:endingPage>602</prism:endingPage></item><item rdf:about="http://www.phytomedicinejournal.com/article/PIIS0944711312000359/abstract?rss=yes"><title>Ardipusilloside inhibits survival, invasion and metastasis of human hepatocellular carcinoma cells</title><link>http://www.phytomedicinejournal.com/article/PIIS0944711312000359/abstract?rss=yes</link><description>Abstract: Ethnopharmacological relevance: Ardipusilloside I is a triterpene-saponin isolated from the Traditional Chinese Medicine Ardisia pusilla A. DC. Its effects and mechanism on invasion and metastasis of liver cancer cells are unclear.Materials and methods: The human hepatocellular carcinoma cell line HepG2 and SMMC-7721 cells were treated with different doses of Ardipusilloside I. Cellular survival, in vitro migration and invasion were evaluated. In vivo metastatic abilities of the HCC cells were detected. We further investigated expression and phosphorylation of Mek, Erk and Akt by using Western blot. MMP2 and MMP9 activities were evaluated by gelatin zymography. E-cadherin expression, Rac1 and Cdc42 activities were examined by Western blot and pull-down assay.Results: Ardipusilloside I inhibited invasion and metastasis of HCC cells both in vitro and in vivo by reducing the protein expressions of metalloproteinase (MMP)-9 and MMP2 proteins. Ardipusilloside I activated Rac1 that enhanced E-cadherin activity and resulted in significantly less metastasis.Conclusion: Our findings indicate that Ardipusilloside I has the potential of inhibition of liver cancer survival, invasion and metastasis both in vitro and in vivo.</description><dc:title>Ardipusilloside inhibits survival, invasion and metastasis of human hepatocellular carcinoma cells</dc:title><dc:creator>Lianqing Lou, Weiwei Ye, Yongxin Chen, Shuang Wu, Linzheng Jin, Jinke He, Xingfei Tao, Jinghong Zhu, Xiangyi Chen, Anmei Deng, Jinhe Wang</dc:creator><dc:identifier>10.1016/j.phymed.2012.01.003</dc:identifier><dc:source>Phytomedicine 19, 7 (2012)</dc:source><dc:date>2012-02-20</dc:date><prism:publicationName>Phytomedicine</prism:publicationName><prism:publicationDate>2012-02-20</prism:publicationDate><prism:volume>19</prism:volume><prism:number>7</prism:number><prism:issueIdentifier>S0944-7113(12)X0005-9</prism:issueIdentifier><prism:section>Oncology and Hematology</prism:section><prism:startingPage>603</prism:startingPage><prism:endingPage>608</prism:endingPage></item><item rdf:about="http://www.phytomedicinejournal.com/article/PIIS0944711312000396/abstract?rss=yes"><title>Induction of apoptosis against cancer cell lines by four ascomycetes (endophytes) from Malaysian rainforest</title><link>http://www.phytomedicinejournal.com/article/PIIS0944711312000396/abstract?rss=yes</link><description>Abstract: Endophytic fungi have been shown to be a promising source of biologically active natural products. In the present study, extracts of four endophytic fungi isolated from plants of the National Park, Pahang were evaluated for their cytotoxic activity and the nature of their active compounds determined. Those extracts exhibiting activity with IC50 values less than 17μg/ml against HCT116, MCF-7 and K562 cell lines were shown to induce apoptosis in these cell lines. Molecular analysis, based on sequences of the rDNA internal transcribed spacers ITS1 and ITS4, revealed all four endophytic fungi to be ascomycetes: three sordariomycetes and a dothideomycete. Six known compounds, cytochalasin J, dechlorogriseofulvin, demethylharzianic-acid, griseofulvin, harzianic acid and 2-hexylidene-3-methyl-succinic acid were identified from a rapid dereplication technique for fungal metabolites using an in-house UV library. The results from the present study suggest the potential of endophytic fungi as cytotoxic agents, and there is an indication that the isolates contain bioactive compounds that mainly kill cancer cells by apoptosis.</description><dc:title>Induction of apoptosis against cancer cell lines by four ascomycetes (endophytes) from Malaysian rainforest</dc:title><dc:creator>Nurul Aqmar Mohamad Nor Hazalin, Kalavathy Ramasamy, Siong Meng Lim, Anthony L.J. Cole, Abu Bakar Abdul Majeed</dc:creator><dc:identifier>10.1016/j.phymed.2012.01.007</dc:identifier><dc:source>Phytomedicine 19, 7 (2012)</dc:source><dc:date>2012-03-07</dc:date><prism:publicationName>Phytomedicine</prism:publicationName><prism:publicationDate>2012-03-07</prism:publicationDate><prism:volume>19</prism:volume><prism:number>7</prism:number><prism:issueIdentifier>S0944-7113(12)X0005-9</prism:issueIdentifier><prism:section>Oncology and Hematology</prism:section><prism:startingPage>609</prism:startingPage><prism:endingPage>617</prism:endingPage></item><item rdf:about="http://www.phytomedicinejournal.com/article/PIIS0944711312000426/abstract?rss=yes"><title>Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin resistant cells</title><link>http://www.phytomedicinejournal.com/article/PIIS0944711312000426/abstract?rss=yes</link><description>Graphical abstract: Abstract: DNA topoisomerases are nuclear enzymes that are the targets for several anticancer drugs. In this study we investigated the antiproliferative activity against human leukaemia cell lines and the effects on topoisomerase I and II of evodiamine, which is a quinazolinocarboline alkaloid isolated from the fruit of a traditional Chinese medicinal plant, Evodia rutaecarpa. We report here the anti-proliferative activity against human leukaemia cells K562, THP-1, CCRF-CEM and CCRF-CEM/C1 and the inhibitory mechanism on human topoisomerases I and II, important anti-cancer drugs targets, of evodiamine. Evodiamine failed to trap [Topo–DNA] complexes and induce any detectable DNA damage in cells, was unable to bind or intercalate DNA, and arrested cells in the G2/M phase. The results suggest evodiamine is a dual catalytic inhibitor of topoisomerases I and II, with IC50 of 60.74 and 78.81μM, respectively. The improved toxicity towards camptothecin resistant cells further supports its inhibitory mechanism which is different from camptothecin, and its therapeutic potential.</description><dc:title>Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin resistant cells</dc:title><dc:creator>Xiaobei Pan, Janet M. Hartley, John A. Hartley, Kenneth N. White, Zhengtao Wang, S.W. Annie Bligh</dc:creator><dc:identifier>10.1016/j.phymed.2012.02.003</dc:identifier><dc:source>Phytomedicine 19, 7 (2012)</dc:source><dc:date>2012-03-09</dc:date><prism:publicationName>Phytomedicine</prism:publicationName><prism:publicationDate>2012-03-09</prism:publicationDate><prism:volume>19</prism:volume><prism:number>7</prism:number><prism:issueIdentifier>S0944-7113(12)X0005-9</prism:issueIdentifier><prism:section>Oncology and Hematology</prism:section><prism:startingPage>618</prism:startingPage><prism:endingPage>624</prism:endingPage></item><item rdf:about="http://www.phytomedicinejournal.com/article/PIIS0944711312000438/abstract?rss=yes"><title>Diallyl sulfide, diallyl disulfide and diallyl trisulfide affect drug resistant gene expression in colo 205 human colon cancer cells in vitro and in vivo</title><link>http://www.phytomedicinejournal.com/article/PIIS0944711312000438/abstract?rss=yes</link><description>Abstract: To elevate chemo-resistance of human cancer cells is a major obstacle in the treatment and management of malignant cancers. Diallyl sulfide (DAS), diallyl disulfide (DADS) and diallyl trisulfide (DATS) are presented in the Alliaceae family particularly in garlic. Although DAS, DADS and DATS have been shown to exhibit anticancer activities, there is little information on effects of these compounds on drug resistant genes in human colon cancer cells in vitro and in vivo. Herein, we are the first to show that DAS, DADS and DATS at 25μM for 24-h and 48-h incubations promoted expression of drug resistant genes in colo 205 human colon cancer cells. In vitro experiments indicated that DATS promoted gene expression of multidrug resistant 1 (Mdr1) (p&lt;0.05), and DAS and DADS promoted MRP3 gene expression and DATS alone stimulated gene expression of multidrug resistance-associated protein-1 (MRP1) (p&lt;0.05) in colo 205 cells. In vivo studies demonstrated that DADS and DATS induced Mdr1 and MRP1 gene expression (p&lt;0.05). DADS promoted MRP3 gene expression (p&lt;0.05) as well as DADS and DATS increased MRP4 and MRP6 gene expression (p&lt;0.05) in the colo 205 xenograft mice. Based on our in vitro and in vivo results, diallyl polysulfides (DAS, DADS and DATS) affected the gene expression of the multidrug resistance in colo 205 human colon cancer cells in vitro and in vivo.</description><dc:title>Diallyl sulfide, diallyl disulfide and diallyl trisulfide affect drug resistant gene expression in colo 205 human colon cancer cells in vitro and in vivo</dc:title><dc:creator>Kuang-Chi Lai, Chao-Lin Kuo, Heng-Chien Ho, Jai-Sing Yang, Chia-Yu Ma, Hsu-Feng Lu, Hui-Ying Huang, Fu-Shin Chueh, Chien-Chih Yu, Jing-Gung Chung</dc:creator><dc:identifier>10.1016/j.phymed.2012.02.004</dc:identifier><dc:source>Phytomedicine 19, 7 (2012)</dc:source><dc:date>2012-03-07</dc:date><prism:publicationName>Phytomedicine</prism:publicationName><prism:publicationDate>2012-03-07</prism:publicationDate><prism:volume>19</prism:volume><prism:number>7</prism:number><prism:issueIdentifier>S0944-7113(12)X0005-9</prism:issueIdentifier><prism:section>Oncology and Hematology</prism:section><prism:startingPage>625</prism:startingPage><prism:endingPage>630</prism:endingPage></item><item rdf:about="http://www.phytomedicinejournal.com/article/PIIS0944711312000451/abstract?rss=yes"><title>Protective effect of extract of Acanthopanax senticosus harms on dopaminergic neurons in Parkinson's disease mice</title><link>http://www.phytomedicinejournal.com/article/PIIS0944711312000451/abstract?rss=yes</link><description>Graphical abstract: Abstract: To study the neuroprotective effect of extract of Acanthopanax senticosus Harms against MPTP-induced mice model of Parkinson's disease and its mechanism. The Parkinson's disease mice model was induced by 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Hydrochloride (MPTP-HCl, 30mg/kg daily for 5 days). High dose group and low dose group were medicated with extract of Acanthopanax senticosus Harms for 20 days, dose amounted to 182mg/kg and 45.5mg/kg daily respectively. The behavioral testing of mice was assessed using pole-climbing test. The levels of Dopamine (DA) and Homovanillic acid (HVA) in striatum were determined by Ultra-performance liquid chromatography combined with time-of-flight mass spectrometry (UPLC-ToF-MS). The levels of dopamine receptor 1 and 2 in striatum were assayed simultaneously with the help of immunohistochemical method. The level of Caspase-3 protein in substantia nigra was analyzed by Western Blot. From Day 5 during the administration of extract of Acanthopanax senticosus Harms, pole-climbing time in low and high dose group were significantly less than model group (p&lt;0.05). Compared with model group, the DA level of striatum in low dose group was significantly higher (p&lt;0.01), the number of dopamine receptor 1 and dopamine receptor 2-positive cells in low and high dose group were significantly less (p&lt;0.05), the Caspase-3 protein level of substantia nigra in low and high dose group were significantly less (p&lt;0.05). The neuroprotective effect of extract of Acanthopanax senticosus Harms may be able to protect C57BL/6 mice against MPTP-induced dopaminergic neuronal damage.</description><dc:title>Protective effect of extract of Acanthopanax senticosus harms on dopaminergic neurons in Parkinson's disease mice</dc:title><dc:creator>Shu-min Liu, Xu-zhao Li, Yan Huo, Fang Lu</dc:creator><dc:identifier>10.1016/j.phymed.2012.02.006</dc:identifier><dc:source>Phytomedicine 19, 7 (2012)</dc:source><dc:date>2012-03-09</dc:date><prism:publicationName>Phytomedicine</prism:publicationName><prism:publicationDate>2012-03-09</prism:publicationDate><prism:volume>19</prism:volume><prism:number>7</prism:number><prism:issueIdentifier>S0944-7113(12)X0005-9</prism:issueIdentifier><prism:section>Neurology</prism:section><prism:startingPage>631</prism:startingPage><prism:endingPage>638</prism:endingPage></item><item rdf:about="http://www.phytomedicinejournal.com/article/PIIS0944711312000517/abstract?rss=yes"><title>Novel Ocimumoside A and B as anti-stress agents: Modulation of brain monoamines and antioxidant systems in chronic unpredictable stress model in rats</title><link>http://www.phytomedicinejournal.com/article/PIIS0944711312000517/abstract?rss=yes</link><description>Abstract: Therapies targeting central stress mechanisms are fundamental for the development of successful treatment strategies. Ocimum sanctum (OS) is an Indian medicinal plant traditionally used for the treatment of various stress-related conditions. Previously, we have isolated and characterized three OS compounds; Ocimarin, Ocimumoside A and Ocimumoside B. However, their role in modulating chronic stress-induced central changes is unexplored. Thus, in the present study the efficacy of these OS compounds have been evaluated on the chronic unpredictable stress (CUS)-induced alterations in the monoaminergic and antioxidant systems in the frontal cortex, striatum and hippocampus, along with the changes in the plasma corticosterone levels. CUS (two different types of stressors daily for seven days) resulted in a significant elevation of plasma corticosterone level, which was reversed to control levels by pretreatment with Ocimumoside A and B (40mg/kg p.o.), while Ocimarin showed no effect. The levels of NA, DA and 5-HT were significantly decreased in all the three brain regions by CUS, with a selective increase of DA metabolites. A significant decrease in the glutathione (GSH) content, the activities of superoxide dismutase and catalase with a significant increase in the glutathione peroxidase activity and lipid peroxidation was observed in all the three regions of the brain by CUS. The OS compounds alone did not cause any significant change in the baseline values of these parameters. However, Ocimumoside A and B (40mg/kg body p.o.) attenuated these CUS-induced alterations with an efficacy similar to that of standard anti-stress (Panax quinquefolium; 100mg/kg p.o.) and antioxidant (Melatonin; 20mg/kg i.p.) drugs. While, Ocimarin failed to modulate these CUS-induced alterations. Therefore, this is the first report which identified the anti-stress activity of novel Ocimumoside A and B at the level of central monoamines and antioxidant properties, implicating their therapeutic importance in the prevention of stress-related disorders.</description><dc:title>Novel Ocimumoside A and B as anti-stress agents: Modulation of brain monoamines and antioxidant systems in chronic unpredictable stress model in rats</dc:title><dc:creator>Ausaf Ahmad, Naila Rasheed, Prasoon Gupta, Seema Singh, Kiran Babu Siripurapu, Ghulam Md Ashraf, Rajnish Kumar, Kailash Chand, Rakesh Maurya, Naheed Banu, Muneera Al-Sheeha, Gautam Palit</dc:creator><dc:identifier>10.1016/j.phymed.2012.02.012</dc:identifier><dc:source>Phytomedicine 19, 7 (2012)</dc:source><dc:date>2012-03-29</dc:date><prism:publicationName>Phytomedicine</prism:publicationName><prism:publicationDate>2012-03-29</prism:publicationDate><prism:volume>19</prism:volume><prism:number>7</prism:number><prism:issueIdentifier>S0944-7113(12)X0005-9</prism:issueIdentifier><prism:section>Neurology</prism:section><prism:startingPage>639</prism:startingPage><prism:endingPage>647</prism:endingPage></item><item rdf:about="http://www.phytomedicinejournal.com/article/PIIS0944711312000372/abstract?rss=yes"><title>Molecular docking and enzyme kinetic studies of dihydrotanshinone on metabolism of a model CYP2D6 probe substrate in human liver microsomes</title><link>http://www.phytomedicinejournal.com/article/PIIS0944711312000372/abstract?rss=yes</link><description>Abstract: The effects of Danshen and its active components (tanshinone I, tanshinone IIA, dihydrotanshinone and cryptotanshinone) on CYP2D6 activity was investigated by measuring the metabolism of a model CYP2D6 probe substrate, dextromethorphan to dextrorphan in human pooled liver microsomes. The ethanolic extract of crude Danshen (6.25–100μg/ml) decreased dextromethorphan O-demethylation in vitro (IC50=23.3μg/ml) and the water extract of crude Danshen (0.0625–1mg/ml) showed no inhibition. A commercially available Danshen pill (31.25–500μg/ml) also decreased CYP2D6 activity (IC50=265.8μg/ml). Among the tanshinones, only dihydrotanshinone significantly inhibited CYP2D6 activity (IC50=35.4μM), compared to quinidine, a specific CYP2D6 inhibitor (IC50=0.9μM). Crytotanshinone, tanshinone I and tanshinone IIA produced weak inhibition, with IC20 of 40.8μM, 16.5μM and 61.4μM, respectively. Water soluble components such as salvianolic acid B and danshensu did not affect CYP2D6-mediated metabolism. Enzyme kinetics studies showed that inhibition of CYP2D6 activity by the ethanolic extract of crude Danshen and dihydrotanshinone was concentration-dependent, with Ki values of 4.23μg/ml and 2.53μM, respectively, compared to quinidine, Ki=0.41μM. Molecular docking study confirmed that dihydrotanshinone and tanshinone I interacted with the Phe120 amino acid residue in the active cavity of CYP2D6 through Pi–Pi interaction, but did not interact with Glu216 and Asp301, the key residues for substrate binding. The logarithm of free binding energy of dihydrotanshinone (−7.6kcal/mol) to Phe120 was comparable to quinidine (−7.0kcal/mol) but greater than tanshinone I (−5.4kcal/mol), indicating dihydrotanshinone has similar affinity to quinidine in binding to the catalytic site on CYP2D6.</description><dc:title>Molecular docking and enzyme kinetic studies of dihydrotanshinone on metabolism of a model CYP2D6 probe substrate in human liver microsomes</dc:title><dc:creator>Xuelin Zhou, Yan Wang, Penelope M.Y. Or, David C.C. Wan, Yiu Wa Kwan, John H.K. Yeung</dc:creator><dc:identifier>10.1016/j.phymed.2012.01.005</dc:identifier><dc:source>Phytomedicine 19, 7 (2012)</dc:source><dc:date>2012-04-30</dc:date><prism:publicationName>Phytomedicine</prism:publicationName><prism:publicationDate>2012-04-30</prism:publicationDate><prism:volume>19</prism:volume><prism:number>7</prism:number><prism:issueIdentifier>S0944-7113(12)X0005-9</prism:issueIdentifier><prism:section>Indication Oriented Research</prism:section><prism:startingPage>648</prism:startingPage><prism:endingPage>657</prism:endingPage></item><item rdf:about="http://www.phytomedicinejournal.com/article/PIIS0944711312000918/abstract?rss=yes"><title>Glycyrrhizic acid (GA), a triterpenoid saponin glycoside alleviates ultraviolet-B irradiation-induced photoaging in human dermal fibroblasts</title><link>http://www.phytomedicinejournal.com/article/PIIS0944711312000918/abstract?rss=yes</link><description>Abstract: Glycyrrhizic acid (GA), a triterpenoid saponin glycoside from the roots and rhizomes of licorice is used in traditional and modern medicine for the treatment of numerous medical conditions including skin diseases and beauty care product. In the present study, we investigated the effect of GA against ultraviolet B (UVB) irradiation-induced photoaging in human dermal fibroblasts (HDFs) and its possible mechanism of action. HDFs were subjected to photoaging by sub-toxic dose of UVB (10mj/cm2) irradiation. Cell viability, matrix metalloproteinase 1 (MMP1), pro-collagen 1, cellular and nuclear morphology, cell cycle, intracellular reactive oxygen species (ROS), caspase 3 and hyaluronidase inhibition assays were performed. Western blotting was used to evaluate the expression of NF-kappa B (NF-κB) and cytochrome-C proteins. GA treatment significantly inhibited photoaging. It achieved this by reducing ROS, NF-κB, cytochrome c, caspase 3 levels and inhibiting hyaluronidase enzyme. The main mechanism seems to be, most likely by blocking MMP1 activation by modulating NF-κB signaling. These findings may be useful for development of natural and safe photoprotective agents against UVB irradiation.</description><dc:title>Glycyrrhizic acid (GA), a triterpenoid saponin glycoside alleviates ultraviolet-B irradiation-induced photoaging in human dermal fibroblasts</dc:title><dc:creator>Quadri Afnan, Mushtaq Dar Adil, Ashraf Nissar-Ul, Ahmad Rather Rafiq, Hussian Faridi Amir, Peerzada Kaiser, Vijay Kumar Gupta, Ram Vishwakarma, Sheikh Abdullah Tasduq</dc:creator><dc:identifier>10.1016/j.phymed.2012.03.007</dc:identifier><dc:source>Phytomedicine 19, 7 (2012)</dc:source><dc:date>2012-04-20</dc:date><prism:publicationName>Phytomedicine</prism:publicationName><prism:publicationDate>2012-04-20</prism:publicationDate><prism:volume>19</prism:volume><prism:number>7</prism:number><prism:issueIdentifier>S0944-7113(12)X0005-9</prism:issueIdentifier><prism:section>Indication Oriented Research</prism:section><prism:startingPage>658</prism:startingPage><prism:endingPage>664</prism:endingPage></item></rdf:RDF>
